Abstract
To the Editor: Maynard and collaborators (April 3 issue)1 report the overexpression of type 3 iodothyronine deiodinase (D3) in gastrointestinal stromal tumors (GISTs), resulting in consumptive hypothyroidism. D3 overexpression is suggested as an inherent property of these tumors, but the authors also acknowledge the possibility of its secondary induction by kinase inhibitors. Indeed, the index patient was treated with sorafenib before the diagnosis of consumptive hypothyroidism, and it is not stated whether any of the additional four patients with hypothyroidism had previously received kinase inhibitors. In a translational protocol of a randomized trial of sunitinib in breast cancer,2 supported by . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
